Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
featured
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

  • 82 views
  • 25 Mar, 2021
  • 1 location
featured
A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis

  • 170 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Crohn's Disease.

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Crohn's Disease.

  • 274 views
  • 08 Nov, 2020
  • 1 location
featured
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 182 views
  • 25 Mar, 2021
  • 1 location
Defining Predictors of RT Response to Vedolizumab in IBD

The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify

  • 12 views
  • 28 Jul, 2021
  • 1 location
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative

  • 8 views
  • 27 May, 2021
  • 20 locations
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

Vedolizumab (VDZ) is a humanized immunoglobulin G1 monoclonal antibody acting against 47 integrin which modulates lymphocyte trafficking in the gut. Results from the adult GEMINI-1 and

inflammatory bowel disease
vedolizumab
enteropathy
monoclonal antibodies
remission
  • 129 views
  • 25 Mar, 2021
  • 14 locations
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of …

  • 0 views
  • 11 Apr, 2021
  • 1 location
Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection

HIV infection returns in the bloodstream. So, there is good treatment, but no cure. The researchers want to test whether a period of treatment with vedolizumab can be used to control HIV infection in

HIV Infection
antiretroviral agents
antiretroviral therapy
immunodeficiency
  • 4 views
  • 19 Feb, 2021
  • 1 location
Fecal Microbial Transplantation and Vedolizumab Treatment of Crohn's Disease

The investigators postulate that by determining a patient's baseline microbiome and manipulating it through fecal microbial transplantation (FMT) may improve response rates to vedolizumab in

vedolizumab
crohn's disease
remission
  • 10 views
  • 24 Jan, 2021
  • 2 locations